# Use of Tocilizumab Drug Levels to Optimize Treatment in RA

> **NCT03895879** · PHASE4 · UNKNOWN · sponsor: **Reade Rheumatology Research Institute** · enrollment: 98 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT03895879
- **Lead sponsor:** Reade Rheumatology Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-01
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2024-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03895879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03895879, "Use of Tocilizumab Drug Levels to Optimize Treatment in RA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03895879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*